Results 71 to 80 of about 742,291 (286)
Frontiers in Molecular Biosciences, 2020 The nuclear protein poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors have been proven effective to potentiate both chemotherapeutic agents and radiotherapy.
Ran Wang +9 more
doaj +1 more source
Chronobiology of Cancer: How Aging Fuels Oncogenesis at the Molecular Level
Aging and Cancer, EarlyView.This graphical abstract illustrates the key biological pathways linking aging with cancer development and progression. In the upper left, cumulative exposure to ultraviolet radiation, toxins, and reactive oxygen species (ROS) causes DNA damage and genomic instability, whereas age‐related decline in repair mechanisms, such as ATM/ATR, BER, and NER ...
Anu Singh, Aroonima Misra, Sufian Zaheer
wiley +1 more source
The combined effect of USP7 inhibitors and PARP inhibitors in hormone-sensitive and castration-resistant prostate cancer cells [PDF]
, 2017 Reduced levels of the tumor suppressor protein CCDC6 sensitize cancer cells to the treatment with PARP-inhibitors. The turnover of CCDC6 protein is regulated by the de-ubiquitinase USP7, which also controls the androgen receptor (AR) stability.
Caterina Miro +18 more
core +1 more source
Advanced Healthcare Materials, EarlyView.Prostate patient‐derived organoids (PDOs) were established from TURP and biopsy specimens with >90% success and retain key features of their tissues of origin, making them functional avatars for antisense oligonucleotide (ASO) therapy . Transfecting single cells outside the Matrigel matrix and then reconstituting organoids overcomes the 3D delivery ...
Thi Thom Tran +15 more
wiley +1 more source
PARP INHIBITORS IN OVARIAN CANCER: TOXICITY PROFILE [PDF]
, 2017 Today, the role of the genetic factor in the etiology of ovarian cancer is unquestionable. Genetic disorders in low-differentiated serous adenocarcinoma of ovaries in about 50 per cent of cases occur in the form of a lack of homologous DNA reparation ...
O. A. SHILKINA, S. V. KHOKHLOVA
core +1 more source
Advanced Science, EarlyView.Dysregulated protein modifications drive tumorigenesis. RINES, an E3 ubiquitin ligase, represses tumor cell proliferation and metastasis by facilitating RING domain‐dependent, ubiquitin–proteasome‐mediated degradation of STAT3 and MYC, which consequently restrains cancer stemness and oncogenic progression.
Lili Li +8 more
wiley +1 more source
Poly(ADP-ribose) polymerase (PARP) and PARP inhibitors
PARP-1 protects cells from endogenous and therapeutically inflicted DNA damage. PARP inhibitors have been under development since 1980 and first entered clinical trial in 2003.
Curtin NJ
core +2 more sources
Homologous Recombination Deficiency, Genetics, PARP Inhibitors, and Screening in Cancer
, 2023 Homologous Recombination Deficiency, Genetics, PARP Inhibitors, and Screening in Cancer, Amy Bodrog, MD, Lipson Cancer Institute Objectives: Discuss how PARP inhibitors work.
Bodrog, Amy
core
Advanced Science, EarlyView.Androgen receptor (AR) drives copper accumulation in prostate cancer while inducing MTF1 to buffer copper toxicity. EP300‐mediated lactylation of MTF1 at K218 promotes its nuclear translocation and metallothionein expression, sequestering cytosolic copper and preventing mitochondrial cuproptosis.
Kai Li +21 more
wiley +1 more source
Frontiers in PharmacologyPoly (ADP-ribose) polymerase (PARP) enzymes are critical in repairing DNA damage induced by chemotherapy and/or radiation. Due to PARP’s role in DNA repair, inhibiting PARP leads to genomic instability and accumulation of damaged cells in cell cycle ...
Dahlia A. Ordaz +5 more
doaj +1 more source